Conjugates based on N-(2-hydroxypropyl)methacryl-amide (HPMA) represent a new generation of polymeric anticancer drugs with improved therapeutic potential and considerably decreased nonspecific side affects.
Conjugates based on N-(2-hydroxypropyl)methacryl-amide (HPMA) represent a new generation of polymeric anticancer drugs with improved therapeutic potential and considerably decreased nonspecific side affects. (en)